A U.S. advisory panel recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combo.
Eli Lilly and Co. said it and partner Pfizer Inc. aim to seek approval by 2018 for a new type of pain drug that could be an alternative to opioids for osteoarthritis, chronic back pain and cancer pain.
Gastric surgery should be offered as a standard treatment option for people with diabetes and could help them control their condition for years without medication, the world’s leading diabetes organizations said.
GlaxoSmithKline’s new inhaled drug Breo proved significantly better than standard care in a large British study that tested it in everyday use after the failure of another big trial in 2015.
Theratechnologies Announces that 82.5% of Patients Achieved the Primary Endpoint in the Phase III Ibalizumab Trial
Theratechnologies Inc. announces that it has been notified by its partner, TaiMed Biologics Inc., of the preliminary results for the primary end point of the phase III trial with ibalizumab in patients with multi-drug resistant HIV-1 (TMB-301).
Novartis AG has seen a number of high profile executives depart the company since the beginning of the year and more C-suite-level employees are planning to exit as well, Reuters reported.
The U.S. PTO is to review UCB’s patent for its epilepsy drug Vimpat, the latest round in a legal battle between the Belgian pharma company and generic rivals.
Indianapolis-based Eli Lilly and Company is on a roll, announcing that between 2014 and 2023, it may launch 20 new products.
Attention deficit hyperactivity disorder (ADHD), usually diagnosed in children, may show up for the first time in adulthood, two recent studies suggest.
The outbreak is expected to reach the continental United States in the coming weeks as temperatures rise and mosquito populations multiply. In interviews with Reuters, more than a dozen state and local health officials and disease control experts say they worry they will have neither the money nor the time to plug gaping holes in the nation’s defenses.